
Dupilumab (anti-IL-4Rα) blocks the IL-4/IL-13 receptor/ligand system



Type I Receptor

B cells, T cells, Monocytes, Eosinophils, Fibroblasts

Type II Receptor

Epithelial cells, Smooth muscle cells, Fibroblasts, Monocytes, Activated B cells

Clinical Update: Dupilumab